CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 3982-A |

# Specialty Guideline Management Fintepla

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Fintepla | fenfluramine |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

Fintepla is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.

All other indications are considered experimental/investigational and not medically necessary.

## Coverage Criteria

### Seizures associated with Dravet syndrome or Lennox-Gastaut syndrome1

Authorization of 12 months may be granted for treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in members 2 years of age and older.

## Continuation of Therapy

Authorization of 12 months may be granted for continuation of treatment in members (including new members) 2 years of age or older requesting reauthorization for an indication listed in the coverage criteria section when the member has achieved or maintained a positive clinical response (e.g., decrease in seizures).

## Other

Due to well documented potential for serious adverse effects, phentermine and fenfluramine are not recommended to be used concurrently. Member cannot use the requested medication concomitantly with phentermine.

## References

1. Fintepla [package insert]. Smyrna, GA: UCB, Inc.; December 2023.